Saturday 17 October 2026
Export PMVP’s income statement to Excel — free account
PMV Pharmaceuticals, Inc.
PMVP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.1% and free cash flow grew 20.3%, each against the same quarter a year earlier.
1.21
0.08
−6.20%
Follow PMVP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
7.70 | 11.14 | 10.09 | 10.76 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.13 | 4.83 | 5.73 | 5.57 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 1.09 | 0.95 | 0.94 | |
Capex/Depreciation |
0.00 | 0.00 | 0.03 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.27) | (0.37) | (0.33) | (0.37) | |
Cash per Share |
1.49 | 1.75 | 2.15 | 2.44 | |
Shareholders Equity per Share |
1.34 | 1.65 | 1.99 | 2.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.34 | 1.65 | 1.99 | 2.28 | |
Free Cash Flow |
(14.58) | (19.68) | (17.20) | (19.82) | |
Working Capital |
70.84 | 87.19 | 103.81 | 120.15 | |
Capital Expenditures |
— | — | (0.01) | 0.00 | |
Net Current Asset Value |
70.84 | 87.19 | 103.38 | 119.60 | |
| Other line items | |||||
Quick Ratio |
7.52 | 10.88 | 9.89 | 10.50 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.27) | (0.37) | (0.33) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.31 | 2.61 | 4.87 | 2.73 | |
Average Assets |
117.46 | 133.59 | 153.93 | 178.67 | |
Average Common Equity |
106.05 | 124.04 | 140.40 | 159.45 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates